CA2302025A1 - Composes 3-oxo-propanenitrile tricycliques - Google Patents

Composes 3-oxo-propanenitrile tricycliques Download PDF

Info

Publication number
CA2302025A1
CA2302025A1 CA002302025A CA2302025A CA2302025A1 CA 2302025 A1 CA2302025 A1 CA 2302025A1 CA 002302025 A CA002302025 A CA 002302025A CA 2302025 A CA2302025 A CA 2302025A CA 2302025 A1 CA2302025 A1 CA 2302025A1
Authority
CA
Canada
Prior art keywords
oxo
methyl
propionitrile
phenyl
isoxazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002302025A
Other languages
English (en)
Inventor
Paolo Pevarello
Carmela Speciale
Mario Varasi
Raffaella Amici
Salvatore Toma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2302025A1 publication Critical patent/CA2302025A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés 3-oxo-propanenitrile tricycliques correspondant à la formule (I), ainsi qu'un sel de ceux-ci, acceptable sur le plan pharmacologique. Dans cette formule Y représente un atome d'azote ou un groupe CH ou N-oxyde, X représente un atome d'oxygène ou NR¿2? dans lequel R¿2? représente alkyle C¿1?-C¿6?, benzyle, pyridyle ou phényle, phényle n'étant pas substitué ou l'étant par un ou deux substituants choisis indépendamment dans le groupe constitué par halogène, trifluorométhyle, alkyle C¿1?-C¿6?, alcoxy C¿1?-C¿6?, nitro, amino, formylamino et alcanoylamino C¿2?-C¿8?, R et R¿1? représentent chacun indépendamment hydrogène, halogène, CF¿3?, alkyle C¿1?-C¿6?, hydroxy, alcoxy C¿1?-C¿6?, alcényloxy C¿3?-C¿4?, nitro, amino, formylamino, alcanoylamino C¿2?-C¿8?, ou alcanoyloxy C¿2?-C¿8?, m vaut zéro ou est un nombre entier compris entre 1 et 6, Q représente alkyle C¿1?-C¿14?, un noyau phényle ou un noyau hétéromonocyclique pentatomique insaturé contenant deux ou trois hétéroatomes choisis parmi oxygène, soufre et azote, le noyau phényle et le noyau hétéromonocyclique n'étant pas substitués ou l'étant pas un ou deux substituants choisis indépendamment dans le groupe constitué par halogène, CF¿3?, alkyle C¿1?-C¿6?, hydroxy, alcoxy C¿1?-C¿6?, nitro, amino, formylamino, alcanoylamino C¿2?-C¿8? ou alcanoyloxy C¿2?- C¿8?, et W représente un groupe -CONH- ou -SO¿2?- ou -CO-. Ces composés et leur sel possèdent une activité inhibitrice de l'enzyme kynurénine-3-hydroxylase.
CA002302025A 1997-10-01 1998-09-23 Composes 3-oxo-propanenitrile tricycliques Abandoned CA2302025A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9720899.5A GB9720899D0 (en) 1997-10-01 1997-10-01 Condensed heterocyclic compounds
GB9720899.5 1997-10-01
PCT/EP1998/006051 WO1999016753A2 (fr) 1997-10-01 1998-09-23 Composes 3-oxo-propanenitrile tricycliques

Publications (1)

Publication Number Publication Date
CA2302025A1 true CA2302025A1 (fr) 1999-04-08

Family

ID=10819928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002302025A Abandoned CA2302025A1 (fr) 1997-10-01 1998-09-23 Composes 3-oxo-propanenitrile tricycliques

Country Status (6)

Country Link
EP (1) EP1019380A2 (fr)
JP (1) JP2001518469A (fr)
AU (1) AU1334399A (fr)
CA (1) CA2302025A1 (fr)
GB (1) GB9720899D0 (fr)
WO (1) WO1999016753A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10021900A1 (de) 2000-05-08 2001-11-15 Bayer Ag Phenyl-substituierte 2-Enamino-Ketonitrile
UY30377A1 (es) 2006-06-02 2008-01-02 Elan Pharm Inc Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3842099A (en) * 1969-10-06 1974-10-15 Teikoku Hormune Mfg Co Ltd Naphtho(2,1-d)isoxazole derivatives
CA1133917A (fr) * 1979-06-11 1982-10-19 Gordon N. Walker Alphacarbamoyl-pyrrolpropionitriles, procede de fabrication, preparations pharmaceutiques renfermant ces composes, et applications therapeutiques
US4435407A (en) * 1982-01-07 1984-03-06 Ciba-Geigy Corporation Certain substituted β-oxo-α-carbamoylpyrrolepropionitriles
GB2127809B (en) * 1982-09-28 1986-03-12 Ciba Geigy Ag Certain b-oxo-a-carbamoyl-pyrrolepropionitriles
US4816467A (en) * 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use
GB8814586D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation
IL92508A0 (en) * 1988-12-08 1990-08-31 Ciba Geigy Ag Novel alpha-cyano-beta-oxopropionamides
GB2227741B (en) * 1989-02-06 1992-08-05 Erba Carlo Spa Condensed 3-oxo-propanenitrile derivatives and process for their preparation
GB8916290D0 (en) * 1989-07-17 1989-08-31 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
JP3148960B2 (ja) * 1993-04-12 2001-03-26 コニカ株式会社 写真用シアンカプラー
JP3542826B2 (ja) * 1994-07-11 2004-07-14 帝国臓器製薬株式会社 新規な二環式化合物縮合［２，１−ｄ］イソキサゾール−３−カルボン酸誘導体

Also Published As

Publication number Publication date
JP2001518469A (ja) 2001-10-16
GB9720899D0 (en) 1997-12-03
WO1999016753A2 (fr) 1999-04-08
EP1019380A2 (fr) 2000-07-19
WO1999016753A3 (fr) 1999-05-20
AU1334399A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
AU773337B2 (en) Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application
ES2224628T3 (es) Inhibidores de pde iii/iv a base de ftalazinonas.
JP4791729B2 (ja) インドール−３−硫黄誘導体
JPH09500147A (ja) 抗炎症剤としてのイソキサゾリン化合物
US5532235A (en) Tricyclic benzazepine vasopressin antagonists
PL183154B1 (pl) Pochodna 2,4-dimetylo-alfa-karboliny, sposób wytwarzania pochodnej 2,4-dimetylo-alfa-karboliny, środek leczniczy zawierający 2,4-dimetylo-alfa-karbolinę, kwas karboksylowy i sposób wytwarzania kwasu karboksylowego
PL180679B1 (en) Derivatives of pyridazinoquinoline
BRPI0616452A2 (pt) quinolinas e seu uso terapêutico
KR20070104592A (ko) Ｍｇｌｕｒ２ 길항제로서의 피라졸로-피리미딘 유도체
EP0503349B1 (fr) Dérivés de l'hydrazone, leur préparation et leur utilisation
US7820691B2 (en) Indoloquinoline compounds as calcium channel blockers
JP2672312B2 (ja) ヘテロアリール３‐オキソ‐プロバンニトリル誘導体及びその製造方法
RU2109735C1 (ru) Оксопропаннитрильные производные конденсированного пиразола или их фармацевтически приемлемые соли, проявляющие иммуностимулирующую активность, и фармацевтическая композиция
MacLeod et al. Identification of 3, 5-dihydro-2-aryl-1H-pyrazolo [3, 4-c] quinoline-1, 4 (2H)-diones as novel high-affinity glycine site N-methyl-D-aspartate antagonists
CA2302025A1 (fr) Composes 3-oxo-propanenitrile tricycliques
KR20150007352A (ko) Kat ii 억제제로서 삼환 화합물
EP0278603B1 (fr) Dérivés condensés de pyrazole et leur procédé de préparation
EP1948166A1 (fr) Derives de carbazole utiles en tant que ligands 5-ht6 fonctionnels
KR900005034B1 (ko) 융합 비사이클릭 이미드 및 그의 제조방법
WO1999006374A1 (fr) Composes heterocycliques condenses
JP2001501180A (ja) 新規なアリールピリダジン
JP2001512107A (ja) 融合ヘテロ環式化合物及びそのキヌレニン−３−ヒドロキシラーゼ阻害剤としての使用
KR910005853B1 (ko) 벤조티오피라노[4,3-c]피리다진 화합물의 제조방법
JP2001518473A (ja) 縮合ベンゾチオピラン化合物
Bhadauria Synthesis and Pharmacological evaluation of some Schiff and Mannich Bases

Legal Events

Date Code Title Description
FZDE Dead